UK SMA Patient Registry Update

We are delighted to announce changes in the UK SMA Patient Registry! These developments will see the collection of information from adults and parents of children and young people living with SMA about their experience of daily life, their activities and quality of life. Also known as patient-reported outcome measures or PROMs, this information will be captured in short online questionnaires in the patient registry.
In the UK, many individuals are now able to receive SMA treatment. The perspective and observations of people living with this condition, about the impact it has on them and how any treatment may change this, is increasingly recognised. This is the drive behind the collection of this information. With patient consent, PROMs information from the patient registry will supplement data from the clinical studies SMA REACH UK (children) and Adult SMA REACH. It will help inform regulatory authorities, clinicians, researchers and pharmaceutical companies about the impact and effectiveness of treatments. It will be important information when regulatory authorities are deciding whether NHS funding of a treatment should continue.
Any parent of a child living with SMA or adult aged 16 years or over can register themselves in the UK SMA Patient Registry at https://www.sma-registry.org.uk/. All participants are encouraged to report their PROMs, in addition to the medical information also collected by the patient registry.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more